Your Patients Are Having Trouble Finding Lantus — Here's How You Can Help

As a prescriber, you've likely heard from patients who can't find Lantus (Insulin Glargine) at their pharmacy. With the discontinuation of Semglee in late 2025 and ongoing insurance formulary transitions, the burden of navigating this supply disruption often falls on patients who are least equipped to handle it — especially those managing complex diabetes regimens.

This guide provides five concrete steps your practice can take to help patients find Lantus, along with alternative recommendations and workflow integrations to manage the situation efficiently.

For a clinical overview of the shortage, see our provider briefing on the Lantus shortage.

Current Availability Snapshot

As of early 2026:

• Brand Lantus (Sanofi): In production. Available in vials and SoloStar pens, though pharmacy-level stock-outs occur in high-demand regions.
• Basaglar (Eli Lilly): Available in KwikPen format. Good overall availability.
• Generic Insulin Glargine: Available from Winthrop and other manufacturers. Regional variability.
• Semglee: Discontinued December 31, 2025. No longer available.
• Toujeo (Sanofi): Available. SoloStar and Max SoloStar pens.
• Tresiba (Novo Nordisk): Available. U-100 and U-200 FlexTouch pens.

Why Patients Can't Find Lantus

Understanding the barriers your patients face helps you intervene more effectively:

Pharmacy-Level Stock Issues

Large chain pharmacies in areas where Semglee was heavily prescribed are experiencing the most stock pressure. These pharmacies are receiving more Insulin Glargine prescriptions than before the Semglee discontinuation, and their ordering systems haven't fully adjusted.

Insurance Barriers

Patients whose plans previously covered only Semglee now face prior authorization requirements, step therapy protocols, or formulary restrictions for brand Lantus. Some patients are being told their insurance won't cover Lantus without PA — even though their plan has added it.

Patient-Level Factors

Many patients don't know that alternatives to Lantus exist, don't have the health literacy to navigate pharmacy switches, or lack transportation to try multiple pharmacy locations. Patients with limited English proficiency face additional barriers.

What Providers Can Do: 5 Actionable Steps

Step 1: Write Flexible Prescriptions

When clinically appropriate, prescribe "Insulin Glargine" by generic name with a note allowing substitution. This gives the dispensing pharmacy flexibility to fill with whatever Insulin Glargine product they have in stock — whether it's brand Lantus, Basaglar, Rezvoglar, or generic Insulin Glargine.

For patients who need a specific product (e.g., due to pen device familiarity or insurance requirements), include a second-choice product on the prescription or document it in the patient's chart.

Step 2: Proactively Reach Out to Semglee Patients

If your practice has patients who were on Semglee, they need new prescriptions. Don't wait for them to call with a problem — pull a report of patients who were prescribed Semglee or Insulin Glargine-yfgn in the past 12 months and contact them proactively.

For each patient:

• Review their current insulin regimen
• Determine insurance coverage for Lantus, Basaglar, or generic alternatives
• Send a new electronic prescription for the covered product
• Document the transition in the chart

Step 3: Direct Patients to Stock-Checking Tools

Recommend that patients use Medfinder to check real-time pharmacy stock before making trips. You can also have your front desk or care coordination team check stock on behalf of patients who struggle with technology.

Consider creating a patient handout or after-visit summary note with:

• The Medfinder URL (medfinder.com)
• Instructions to search for "Lantus" or "Insulin Glargine"
• Tips to try independent pharmacies and call early in the week

Step 4: Pre-Authorize Where Possible

For patients whose insurance requires prior authorization for Lantus or alternatives, submit PAs proactively rather than waiting for pharmacy rejections. Document:

• The patient's diagnosis (type 1 or type 2 diabetes)
• Previous stable use of Insulin Glargine (Semglee or other)
• Clinical rationale for Insulin Glargine continuation
• Semglee discontinuation as the reason for product change

Most insurers are expediting PAs related to the Semglee transition, but proactive submission prevents gaps in coverage.

Step 5: Connect Patients With Financial Assistance

Cost is a barrier for many patients, especially those switching to brand Lantus from lower-cost Semglee. Make sure patients know about:

• Sanofi Valyou Savings Program: $35/month for Lantus — insured or uninsured
• Sanofi Copay Savings Card: $0-$35 copay for commercially insured patients
• Medicare insulin cap: $35/month under the Inflation Reduction Act
• Sanofi Patient Connection: Free Lantus for eligible uninsured patients
• GoodRx / SingleCare coupons: Can reduce costs to $35-$100

For a comprehensive patient-facing resource, share our savings guide for Lantus. For provider-specific cost strategies, see our provider guide to saving patients money on Lantus.

Alternative Basal Insulins to Consider

When Lantus isn't available or isn't covered, these alternatives provide equivalent or superior basal coverage:

• Basaglar (Insulin Glargine, Eli Lilly): Same molecule as Lantus. KwikPen format. 1:1 dose conversion. Often preferred on insurance formularies.
• Generic Insulin Glargine: Therapeutically equivalent. Lowest cost option with coupons ($35-$75).
• Toujeo (Insulin Glargine U-300, Sanofi): Concentrated formulation. May be better for patients on high basal doses or those experiencing nocturnal hypoglycemia. Not a 1:1 dose conversion — patients may need 10-18% more units.
• Tresiba (Insulin Degludec, Novo Nordisk): Different molecule with up to 42-hour duration. More flexible dosing schedule. Lower nocturnal hypoglycemia risk. Higher cost ($300-$500+ without coupons).

For a patient-facing comparison, see our Lantus alternatives guide.

Workflow Tips for Your Practice

Integrating supply awareness into your clinical workflow doesn't have to be complicated:

• Add a shortage flag to your EHR: Flag Insulin Glargine prescriptions with a note about current supply issues so clinical staff are prepared to address patient questions
• Create a PA template: Pre-populate prior authorization forms with standard language about the Semglee discontinuation to speed up submissions
• Designate a point person: Assign one staff member (MA, RN, or pharmacy liaison) to monitor insulin availability and serve as the practice resource for patients with access issues
• Stock patient handouts: Keep printed or digital handouts with Medfinder instructions, savings program details, and alternative insulin information available for patients
• Schedule follow-ups: For patients transitioning to a new insulin product, schedule a follow-up within 2-4 weeks to check blood glucose control and adjust doses as needed

Final Thoughts

The Insulin Glargine supply disruption requires a proactive, systems-level response from practices — not just one-off prescription changes. By writing flexible prescriptions, proactively reaching out to affected patients, directing them to tools like Medfinder, and connecting them with financial assistance, you can significantly reduce the burden on your patients and your staff.

This disruption is temporary, but the practice workflows you build now will serve you well the next time a critical medication faces supply challenges.